PASTEUR Act of 2026

The PASTEUR Act of 2026 establishes a government program to financially support the development and commercial availability of new antibiotics needed to fight drug-resistant infections. Under this bill, the Secretary of Health and Human Services can enter into contracts with pharmaceutical sponsors to provide annual payments ranging from $75 million to $300 million for drugs that treat specific resistant pathogens and address unmet medical needs. To receive these funds, companies must agree to manufacture the drugs in the United States, report resistance data, educate healthcare professionals on proper usage, and adhere to environmental best practices. The legislation also creates a new advisory group to evaluate drug applications and authorizes grant programs to help hospitals and outpatient clinics improve their antibiotic stewardship and resistance monitoring.